Skip to main content

Table 3 Listing of the most common adverse events occurring in ≥ 10% patients in either treatment group (safety population)

From: Pertuzumab in combination with trastuzumab and chemotherapy for Chinese patients with HER2-positive metastatic gastric or gastroesophageal junction cancer: a subpopulation analysis of the JACOB trial

Most common AE Pertuzumab group [cases (%)] n = 83 Control group [cases (%)] n = 80
Any grade Grade 3–5 Any grade Grade 3–5
Neutropenia 60 (72.3) 31 (37.3) 52 (65.0) 24 (30.0)
Leukopenia 53 (63.9) 14 (16.9) 47 (58.8) 12 (15.0)
Nausea 52 (62.7) 7 (8.4) 49 (61.3) 2 (2.5)
Anemia 50 (60.2) 20 (24.1) 43 (53.8) 18 (22.5)
Vomiting 38 (45.8) 9 (10.8) 36 (45.0) 6 (7.5)
Decreased appetite 37 (44.6) 3 (3.6) 29 (36.3) 1 (1.3)
Diarrhea 33 (39.8) 7 (8.4) 13 (16.3) 1 (1.3)
Thrombocytopenia 31 (37.3) 5 (6.0) 28 (35.0) 7 (8.8)
Fatigue 26 (31.3) 2 (2.4) 16 (20.0) 1 (1.3)
Hypokalemia 19 (22.9) 6 (7.2) 11 (13.8) 4 (5.0)
Abdominal distension 18 (21.7) 1 (1.2) 12 (15.0) 0
Palmar-plantar erythrodysesthesia syndrome 14 (16.9) 5 (6.0) 16 (20.0) 6 (7.5)
Creatinine renal clearance decreased 13 (15.7) 0 10 (12.5) 0
Constipation 11 (13.3) 0 12 (15.0) 0
Weight decreased 13 (15.7) 1 (1.2) 4 (5.0) 0
Stomatitis 14 (16.9) 3 (3.6) 7 (8.8) 1 (1.3)
Pyrexia 9 (10.8) 0 12 (15.0) 0
  1. AE adverse event